A run of September developments is showing where pressure is building across clinical-trial infrastructure.

DHL is adding specialist pharmaceutical and cold-chain capacity in Singapore, while THREAD has launched technology to bring fragmented participant, device and operational data into a single environment. The FDA has also opened its Expedited Investigational New Drug (IND) Pilot, testing whether earlier collaboration and rolling review can shorten the path to first-in-human trials.

Together, the developments highlight two growing demands on trial infrastructure: tighter control of increasingly specialised products and better visibility across data, systems and locations.

Visiongain values the global Clinical Trial Supply and Logistics Market for Pharma at US$7.92bn in 2026, rising to US$18.22bn by 2036 at a CAGR of 8.7%.

Visiongain Top Takeaways

• Cold-chain investment is focusing on control as well as capacity: DHL and UPS are putting money into temperature integrity, visibility and fewer vulnerable hand-offs across healthcare supply chains.
• Fragmented trial data is becoming an execution problem: Connecting participant, device and operational information can help sponsors identify risks earlier across distributed studies.
• Faster development leaves less room for operational delay: The FDA’s new Expedited IND Pilot adds to the pressure for supply, sites and supporting systems to be ready sooner.

Cold-Chain Investment Targets Tighter Control

DHL is expanding its healthcare logistics network in Singapore with a S$22 million Coldchain Hub, a second pharmaceutical hub and dedicated GDP-compliant healthcare space at its South Asia Hub.

Due to open in late 2027, the Coldchain Hub will provide dedicated 2°C to 8°C and 15°C to 25°C handling environments with direct access to air freight. DHL says the facility is designed to maintain an unbroken cold chain from aircraft through to customers’ warehouses, reducing temperature exposure during transfers.

UPS is investing at the same pressure points. In June, it committed US$48 million to 27 temperature-controlled cross-dock facilities globally, providing short-term storage between air and ground transport while maintaining required temperatures.

The investments show how cold-chain competition is extending beyond refrigerated capacity. Both companies are putting infrastructure around the points where sensitive products change hands, with greater emphasis on temperature integrity, visibility and chain of custody. Transfer points are becoming a focus of investment because failures there can compromise product integrity and disrupt increasingly specialised supply chains.

Not all of this capacity is dedicated to clinical trials, but the same capabilities are important for advanced therapies and other temperature-sensitive investigational products.

Trial Data Is Getting Harder to Connect

THREAD is targeting another pressure point in clinical development: the growing number of data sources that study teams have to bring together.

On 9 September, the company launched new capabilities to standardise participant, device and operational data from multiple sources in decentralised and hybrid trials. The platform connects participant interactions, digital health technologies, operational information and external systems, with THREAD saying this can help sponsors and CROs identify emerging risks earlier.

The challenge is becoming more visible as wearables, eCOA, remote monitoring and third-party platforms add new streams of information to clinical studies. The problem is no longer simply collecting the data, but making it usable across systems and teams.

THREAD is not alone in targeting that gap. Clinical-data company nPhase launched a new platform the same week aimed at harmonising information from disparate systems, while Signant Health’s acquisition of Ametris earlier this year brought patient-reported and wearable-derived data together within one offering.

The commercial direction is becoming clearer. As sponsors work with more digital tools and data sources, technology providers are competing on their ability to reduce fragmentation, connect workflows and turn study data into information that can be acted on earlier.

FDA Pilot Puts Trial Readiness in Focus

The FDA’s new Expedited IND Pilot adds another dimension to the infrastructure question.

Launched on 15 September, the programme will test whether earlier collaboration with qualified research institutions and rolling review of IND components during the pre-IND phase can shorten the path to first-in-human trials. The FDA also wants activities such as IRB review and site activation to run in parallel where appropriate.

The initial cohort will be small, with only eight to ten sponsor-institution pairs expected to take part. But the model being tested is significant: if regulatory preparation and trial start-up become more concurrent, operational readiness has to move earlier too.

Supply, sites and supporting systems need to be ready when a programme advances, rather than becoming the next source of delay.

Market Outlook: Value Moves to the Interfaces

The recent activity suggests that value in clinical-trial infrastructure is increasingly tied to how well providers manage the points where products, data and responsibilities change hands.

That has implications for competition. Scale and geographic reach remain important, but they do not solve fragmented data, vulnerable cold-chain transfers or delays between regulatory preparation and trial start-up. Providers that can make those interfaces easier to manage have a clearer role in reducing execution risk.

The same consideration could increasingly shape supplier decisions. Sponsors and CROs do not only need individual services to perform well; they need logistics, technology and trial operations to work together without creating additional points of failure.

Visiongain Insight: The next source of value in clinical-trial infrastructure is likely to sit at the interfaces: where products change hands, data moves between systems and trial-start activities converge. Providers that can make those hand-offs more reliable and visible will be better placed as sponsors seek to accelerate development without adding operational risk.

From Visiongain

Visiongain provides market intelligence across healthcare, pharma and biotech, helping organisations assess changing market dynamics, emerging growth areas and the commercial implications of developments across the life sciences sector.

Our research combines market forecasts, competitive analysis and sector insight to support strategic planning, investment and business development.

Related Research:

• Clinical Trial Supply and Logistics Market 2026-2036
• Women’s Clinical Trials & CROs Market Report 2026-2036
• Decentralised Clinical Trials Market Report 2026-2036

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com